Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07490418

TES HT100 Clinical Validation for Brain Injury Screening in Patients With Mild Head Trauma or Neurological Symptoms

The goal of this clinical study is to evaluate how accurately and safely the TES HT100 device can identify intracranial abnormalities in adult emergency department patients with mild head trauma or neurological symptoms that are not related to trauma and are not immediately life-threatening. The main questions it aims to answer are:

* How well does TES HT100 identify patients with intracranial abnormalities compared with head CT, the reference standard? * Is TES HT100 safe to use in this patient population? * Could TES HT100 help improve patient triage and use of hospital resources in the emergency setting?

Researchers will compare the result of TES HT100 with the head CT report.

Participants will:

* Be enrolled if they are adults presenting to the emergency department with mild head trauma or selected neurological symptoms * Undergo standard clinical assessment and head CT according to usual care * Have an additional TES HT100 examination lasting about 5 minutes, performed by trained personnel * Be assessed for device performance and any adverse events related to use of the device

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pineta Grande Hospital

Castel Volturno, CE, 81030, Italy

Location status: Recruiting

Location contact

Angelo Localzo, Registered Nurse

SUB_INVESTIGATOR

Dorotea Cerbarano

CONTACT

[email protected]

+39-0823-854111

Esaù Russo, Registered Nurse

SUB_INVESTIGATOR

Modestina Adriana Conte, MD

PRINCIPAL_INVESTIGATOR

About this study

This is a prospective, multicenter, open-label clinical investigation evaluating the TES HT100 as a non-invasive adjunctive screening device for detection of intracranial abnormalities in adult Emergency Department patients. The study is being conducted in three centers in Italy and Poland.

TES HT100 is intended for non-invasive detection of endocerebral lesions. The device used in this investigation is TES HT model 100, equipped with software version 1.3 or later and firmware version 1.4 or later, in the same configuration planned for commercialization. The system uses non-ionizing, ultra-low-power electromagnetic waves in the 500-6500 MHz frequency range and provides a binary result indicating the presence or absence of intracranial abnormality. The examination is brief, with an overall duration of about 5 minutes.

The study is designed to evaluate the diagnostic performance and safety of TES HT100 when used in addition to standard emergency care. Participants undergo routine clinical assessment and brain CT according to usual clinical practice, and the TES HT100 examination is performed as an add-on procedure. The reference standard for performance evaluation is the brain CT report. TES HT100 is not intended to replace standard clinical assessment or CT imaging.

To reduce interpretation bias, the TES HT100 examination is performed by trained personnel who do not have access to the CT report at the time of testing, and the radiologist interpreting the CT scan is blinded to the TES HT100 result. TES HT100 examinations are performed within 24 hours before or after CT, according to site workflow.

The investigation plans to enroll approximately 850 participants overall across two clinical cohorts. The study duration is planned to be 30 months. Three TES HT100 devices, one per participating center, will be used under the same qualification and maintenance procedures.

In addition to diagnostic validation against CT, the study includes safety monitoring during device use and an exploratory assessment of the potential clinical utility of TES HT100 in emergency department triage and resource management. The overall objective is to generate clinical evidence on the performance and safety of TES HT100 as a rapid, non-invasive screening support tool in the emergency setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age greater than 18 years
  • Provision of informed consent
  • Presentation to the Emergency Department with mild head injury, or
  • Presentation to the Emergency Department for non-traumatic neurological symptoms and not in a critical condition, including:
  • syncope
  • spatial disorientation and/or loss of balance
  • speech disturbance and/or facial hemi-paresis
  • visual alterations
  • memory loss and/or confusional state

Exclusion criteria

  • Age less than 18 years
  • Pregnant women
  • Metal plates or metal prostheses installed in the skull cap
  • Severe head trauma and/or extensive lacerated-contused areas
  • Critical condition
  • Visible skull fracture
  • Failure or inability to provide signed informed consent

Treatment and study plan

Temnographic Brain Screening Examination

Diagnostic Test

A non-invasive, add-on diagnostic examination performed with the TES HT100 device to assess the presence or absence of intracranial abnormality in adult emergency department patients. The device uses ultra-low-power, non-ionizing electromagnetic waves in the 500-6500 MHz range and provides a binary on/off result. The examination lasts about 5 minutes, does not require direct contact with the patient's head, and is performed by trained personnel in addition to standard clinical evaluation and head CT.

Primary outcomes

  1. Diagnostic accuracy of TES HT100 for detection of intracranial abnormalities

    Time frame: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

    Diagnostic performance of TES HT100 compared with the head CT report as the reference standard, assessed by ROC-AUC and by sensitivity and specificity for identification of intracranial abnormalities.

  2. Rate of device-related adverse events

    Time frame: From TES HT100 examination through study participation completion, an average of 1 year

    Incidence and type of adverse events related to the use of TES HT100 during the study.

Secondary outcomes

  1. Operator time associated with TES HT100-supported screening

    Time frame: Day 1

    Descriptive evaluation of operator time associated with use of TES HT100 during emergency department screening, based on the number of TES HT100 examinations performed per participant and the approximate duration of each examination (about 5 minutes), as described in the protocol.

  2. Procedures associated with TES HT100-supported screening

    Time frame: Day 1

    Descriptive evaluation of workflow-related procedures associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol. This may include patient handling or organizational procedures required during the diagnostic pathway, such as patient transfer to a different bed or room or need for additional staff support.

  3. Costs associated with TES HT100-supported screening

    Time frame: Day 1

    Descriptive evaluation of resource use and related cost considerations associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol.

  4. Diagnostic performance of TES HT100 in predefined patient subgroups

    Time frame: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

    Analysis of TES HT100 diagnostic performance, based on sensitivity and specificity versus head CT, in predefined subgroups, including younger patients, older patients, patients with or without prior injury or brain surgery, and patients with or without neurodegenerative disease.

Study contacts

Contact information is provided by the study sponsor or research team.

Fabrizio Alfieri

CONTACT

[email protected]

+39-081-19189806

Sponsors and collaborators

Lead sponsor

B&B srl

Industry

Registry information

Official study title

TES HT100 Clinical Outcomes - Clinical Validation of the TES HT100 Temnograph for Brain Injury Screening in Patients With Mild Head Trauma or Suspected Neurological Symptoms (TESCO)

Acronym: TESCO

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 24, 2026
Registry last updated
Mar 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.